What is the outlook for the pharmaceutical industry in 2020

In 2018, the total global pharmaceutical expenditure reached a trillion US dollars, and it is expected to approach one trillion US dollars by 2019, with a global growth rate of 4%-5%. It is expected that by 2023, the market will still maintain a growth level of 5%, and the total global pharmaceutical expenditure will exceed one trillion US dollars, driven by the application of innovative drugs in developed markets and the expansion of drug market access and use in emerging markets.

Among developed markets, the U.S. is still the largest, accounting for about one-third of the global market, and is expected to reach $600 billion by 2023.

The data shows that in the past ten years, with the rapid development of China's economy, the continuous improvement of the living standards of Chinese residents, the impact of factors such as the reform of the domestic medical system and the gradual aging of the population have been positive, which is conducive to the rapid development of the domestic pharmaceutical market, in 2014, the scale of China's pharmaceutical market exceeded one trillion yuan, and in 2019, it has reached about one trillion yuan. China's pharmaceutical market will continue to maintain a growth rate comparable to that of previous years, and reach about one trillion yuan in 2023.

Biomedical CDMO (Contract Development and Manufacturing Organization) is a service-oriented enterprise that provides customized services for biomedical R&D and production. With the improvement of people's health awareness and the continuous development of biomedical technology, biomedical CDMO has been widely used and promoted around the world, and the future development prospects are very broad. Here are a few reasons why:

Continued growth in market demand: The growing market demand in the biomedical field is mainly affected by factors such as an aging population, an increasing incidence of chronic diseases, and accelerated research and development of new drugs. This will further promote the development and application of biomedical CDMOs.

Technological innovation continues to advance: Biomedical CDMO continues to advance in technological innovation, such as the application and research and development of new technologies such as monoclonal antibodies, genes, and cells, which provide a wider range of services and business opportunities for biomedical CDMOs.

Increased policy support: The support of biomedical CDMO in various countries has been increasing, including tax incentives, policy subsidies, R&D support, etc., which will further promote the development and application of biomedical CDMO.

Fierce market competition: Although the market for biomedical CDMO is promising, it is also facing fierce market competition. Therefore, biomedical CDMOs need to continuously improve their technical level, reduce costs, and improve service quality to maintain market competitiveness.

In short, the development prospects of biomedical CDMO in the future are very broad, but it also faces challenges in market competition, technological innovation, policy support and other aspects. Only by continuously improving the technical level, reducing costs and improving service quality can we be invincible in the market competition.

Pharmaceutical stocks will still have ** in the next few yards, and **will not be small! There are several reasons for this:

1. The ** value of the pharmaceutical sector, low risk! In the 29 years since the establishment of A-shares, the pharmaceutical sector has been identified by the market as a highly defensive sector, but the price is very high, and pharmaceutical stocks are still the key defensive sectors in the industry. And the ** of the pharmaceutical sector is often the base of the origin of **, value stocks, and slow bulls, so once ** improves, many long-term funds will still pour into these ** layout!

2. The time has not yet come! Take the medicine ** will only be late, will not be absent! The current ** of A shares is actually an accumulation of popularity and the repair of the index, so the first batch of ** is mainly concentrated in financial stocks, heavyweight stocks, big blue chips, big white horses, and hot spots under some concept hype**.

3. The trend of Chinese population dividend, the vast majority of the 1.4 billion people are inseparable from seeing a doctor and taking medicine! 400 million of China's 1.4 billion people are inseparable from drugs, especially those diseases that we commonly use and some diseases that require long-term medication, so this has brought sustained profitability and growth to many medical sectors such as medical treatment and drug production!

Please click to enter a description (up to 18 words).